Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Darío Sanchez-Cabrero"'
Autor:
Carmen Rodríguez-Jiménez, Alberto Peláez-García, Carlos Rodriguez-Antolin, Oliver Higuera, Darío Sanchez-Cabrero, Javier de Castro, Rocío Rosas-Alonso, Inmaculada Ibáñez de Cáceres, Patricia Cruz, V.E.F. Montaño, Isabel Esteban-Rodríguez
Publikováno v:
The Oncologist
Identifying the druggable target is crucial for patients with nonsquamous advanced non‐small cell lung cancer (NSCLC). This article adds to the spectrum of ROS1 fusion cases described in NSCLC. We describe a novel SLC12A2‐ROS1 rearrangement that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2addf53a7637d642f0fe4536995a41b
https://doi.org/10.1002/onco.13745
https://doi.org/10.1002/onco.13745
Autor:
J. Villamayor, Eugenia Espinosa, J Pedregosa, Ana Custodio, Darío Sanchez-Cabrero, D. Viñal, Beatriz Castelo, L Gutierrez-Sainz, Virginia Martínez-Marín, P. Zamora, J A Garcia-Cuesta, Andrés Redondo, J de Castro-Carpeño, Alvaro Pinto, Oliver Higuera, J. Feliu, Patricia Cruz, A Gallego, D. Martinez-Perez
Publikováno v:
Clinical and Translational Oncology. 23:1245-1252
Cancer and cancer therapies have been associated with an increased incidence of venous thromboembolic events (VTE). However, the incidence of VTE in patients on immunotherapy has not been well characterized. The aim of this study was to assess the in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8a5edc3b58909f7ce7d4ab571f72dc0
https://doi.org/10.1007/s12094-020-02515-3
https://doi.org/10.1007/s12094-020-02515-3
Autor:
J. de Castro, J A Garcia-Cuesta, J. Feliu, L Gutierrez-Sainz, Nuria Rodríguez-Salas, Eugenia Espinosa, Daniel Tirapu Martínez, L. Ostios, Alvaro Pinto, Oliver Higuera, J Pedregosa, J. Villamayor, D. Viñal, Darío Sanchez-Cabrero
Publikováno v:
Clinical and Translational Oncology. 23:1185-1192
The prognostic value of neutrophil-to-lymphocyte ratio (NLR) has been extensively studied in cancer patients. However, the performance of NLR as an early marker of efficacy of immune checkpoint inhibitors (ICI) is still understudied. We studied the u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cb5feb4a821a7b5b279d9ac3130ec82
https://doi.org/10.1007/s12094-020-02509-1
https://doi.org/10.1007/s12094-020-02509-1
Autor:
Olga Pernía, Sara Palacios-Zambrano, Itsaso Losantos-Garcia, Inmaculada Ibanez-de-caceres, Isabel Esteban, Darío Sanchez-Cabrero, Ismael Ghanem, Virginia Martínez-Marín, Rocío Rosas-Alonso, Carlos Rodriguez-Antolin, Julian Colmenarejo-Fernandez, Gema Moreno-Bueno, Javier de Castro
Publikováno v:
Clinical Epigenetics
Digital.CSIC. Repositorio Institucional del CSIC
instname
Biblos-e Archivo. Repositorio Institucional de la UAM
Digital.CSIC. Repositorio Institucional del CSIC
instname
Biblos-e Archivo. Repositorio Institucional de la UAM
© The Author(s) 2021.
[Background]: The promoter hypermethylation of the methylguanine-DNA methyltransferase gene is a frequently used biomarker in daily clinical practice as it is associated with a favorable prognosis in glioblastoma patients
[Background]: The promoter hypermethylation of the methylguanine-DNA methyltransferase gene is a frequently used biomarker in daily clinical practice as it is associated with a favorable prognosis in glioblastoma patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d0c2cde520cada429a8c44b04fcaba1
https://pubmed.ncbi.nlm.nih.gov/33750464
https://pubmed.ncbi.nlm.nih.gov/33750464
Autor:
Isabel Esteban, Darío Sanchez-Cabrero, Ismael Ghanem, Carlos Rodriguez-Antolin, Javier de Castro, Julian Colmenarejo-Fernandez, Virginia Martínez-Marín, Rocío Rosas-Alonso, Inmaculada Ibáñez de Cáceres, Itsaso Losantos-Garcia, Olga Pernía
The promoter hypermethylation of the methylguanine-DNA methyltransferase (MGMT) gene is a frequently used biomarker in daily clinical practice as it is associated with a favorable prognosis in glioblastoma patients treated with temozolamide. In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2339d159bb50a8fa074bc832bbb7dde7
https://doi.org/10.20944/preprints202008.0096.v1
https://doi.org/10.20944/preprints202008.0096.v1
Autor:
Inmaculada Ibáñez de Cáceres, Rocío Rosas, Carlos Rodriguez-Antolin, Miranda Burdiel, P. Cruz, Darío Sanchez-Cabrero, Itsaso Losantos, Olga Pernía, Julia Jimenez, Javier de Castro
Publikováno v:
Cancer Research. 81:2381-2381
Background: Non-small cell lung cancer (NSCLC) is one leading cause of death worldwide, with a 5-year survival rate of only 24%. Late diagnosis and the innate or acquired anti-cancer drug resistance are the main causes of this high mortality. In rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a9c00c486a777c96ec676e25f64703f
https://doi.org/10.1158/1538-7445.am2021-2381
https://doi.org/10.1158/1538-7445.am2021-2381
Autor:
Patricia Cruz, Pilar Santisteban, Darío Sanchez-Cabrero, María Palomares-Bralo, Veronica Pulido, Rocío Rosas, Alvaro García-Guede, Javier de Castro, Carmen Rodriguez, MDolores Diestro, Inmaculada Ibáñez de Cáceres, Carlos Rodriguez-Antolin, Olga Vera, Rubén Martín-Arenas, Olga Pernía, Ana Sastre-Perona
SUMMARYDespite often leading to platinum resistance, platinum-based chemotherapy continues to be the standard treatment for many epithelial tumors. In this study we analyze the cytogenetic alterations that arise after cisplatin treatment providing no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71390574d6d5e4826928db3c9da80f8d
https://doi.org/10.1101/517169
https://doi.org/10.1101/517169